IP Library Granted Patent US 9,096,893
Granted Patent B2
US 9,096,893 · App. 13/941,122 · Granted Aug 4, 2015

Methods for analysis of nucleic acid molecules during amplification reactions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,096,893
App. No.
13/941,122
Granted
Aug 4, 2015
Kind
B2
Abstract

The present invention provides systems, methods and kits for performing a detection assay (e.g., invasive cleavage assay) in combination with an amplification assay (e.g., PCR), where the detection assay employs enzyme footprint probes with relatively short (e.g., 6-12 bases) analyte-specific regions configured to provide a preferred footprint length of duplex for use with a particular nucleic acid modifying enzyme. In some embodiments, such assays are used for target quantification, and in other embodiments, such assays are used for genotyping. In certain embodiments, the use of such short probes allows for assays with increased dynamic range.

Claims (28)

1. A method of analyzing a target nucleic acid, comprising:

a) amplifying a target nucleic acid in the presence of a synthetic probe and a thermostable FEN-1 endonuclease under conditions such that said synthetic probe is cleaved during an amplification reaction to generate cleaved fragments;

wherein said synthetic probe is a footprint probe comprising an analyte-specific portion and a non-target portion, wherein said non-target portion is substantially non-complementary to said target nucleic acid and wherein said analyte-specific portion is no more than 12 nucleotides in length, and contains up to 12 nucleotides that are complementary to said target nucleic acid, and

wherein, if said amplifying is done in an isothermal reaction, said analyte-specific portion of said footprint probe has a calculated T m with said target that is at least 5° C. below the temperature at which said isothermal reaction is conducted, or if said amplifying is done in a thermal cycling reaction, said analyte-specific portion of said footprint probe has a calculated T m with said target that is at least 5° C. below the lowest temperature used in said thermal cycling; and

b) detecting said cleaved fragments during said amplification reaction.

2. The method of claim 1 , wherein, if said amplifying is done in an isothermal reaction, said analyte-specific portion of said footprint probe has a calculated T m with said target that is at least at least 8° C. below the temperature at which said isothermal reaction is conducted, or if said amplifying is done in a thermal cycling reaction, said analyte-specific portion of said footprint probe has a calculated T m with said target that is at least 8° C. below the lowest temperature used in said thermal cycling.

3. The method of claim 1 , wherein, if said amplifying is done in an isothermal reaction, said analyte-specific portion of said footprint probe has a calculated T m with said target that is at least at least 10° C. below the temperature at which said isothermal reaction is conducted, or if said amplifying is done in a thermal cycling reaction, said analyte-specific portion of said footprint probe has a calculated T m with said target that is at least 10° C. below the lowest temperature used in said thermal cycling.

4. The method of claim 1 , wherein said synthetic probe is unlabeled.

5. The method of claim 1 , wherein said synthetic probe does not contain non-natural nucleotides and/or does not contain a minor groove binder moiety.

6. The method of claim 1 , wherein said non-target portion of said synthetic probe is at least 10 nucleotides in length.

7. The method of claim 1 , wherein said amplifying employs amplification primer oligonucleotides, and wherein said analyte specific portion of said synthetic probe has a calculated T m with respect to said target nucleic acid substantially below the calculated T m of said amplification primer oligonucleotides with which it is used.

8. The method of claim 1 , wherein said analyte specific portion of said probe contains no more than 11 nucleotides.

9. The method of claim 1 , wherein said analyte specific portion of said probe contains no more than 10 nucleotides.

10. The method of claim 1 , wherein said analyte specific portion of said probe contains no more than 9 nucleotides.

11. The method of claim 1 , wherein said analyte specific portion of said probe contains no more than 8 nucleotides.

12. The method of claim 1 , wherein said analyte specific portion of said probe contains no more than 7 nucleotides.

13. The method of claim 1 , wherein said analyte specific portion of said probe contains no more than 6 nucleotides.

14. The method of claim 1 , wherein a cleavage structure is formed before said probe is cleaved, wherein said cleavage structure is formed by association of said target nucleic acid with:

a) said synthetic probe at a first region of said target nucleic acid; and

b) a second oligonucleotide at a second region of said target nucleic;

wherein said second region is downstream of said first region of said target nucleic acid.

15. The method of claim 14 , wherein said second region of said target nucleic acid is contiguous with said first region.

16. The method of claim 15 , wherein in said cleavage structure, at least one nucleotide at the 3′ end of said second oligonucleotide overlaps with a region of hybridization between said probe and said target nucleic acid.

17. The method of claim 16 , wherein in said cleavage structure, the 3′ terminal nucleotide of said second oligonucleotide is not complementary to said target nucleic acid.

18. The method of claim 14 , wherein said second oligonucleotide is also a primer oligonucleotide used in said amplifying.

19. The method of claim 1 , wherein said detecting said cleaved fragments comprises associating one or more of said cleaved fragments with a synthetic detection oligonucleotide.

20. The method of claim 19 , wherein said synthetic detection oligonucleotide comprises a label.

21. The method of claim 1 , wherein said cleaved fragments, when associated with said synthetic detection oligonucleotide, form a cleavage structure that is cleavable by said thermostable FEN-1 endonuclease.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE R/F 031393 0179 Recorded Jul 17, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 036127/0804 →
SECURITY AGREEMENT Recorded Oct 8, 2013
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIOP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 031393/0179 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2013
From: ALLAWI, HATIM
To: HOLOGIC, INC.
Reel/Frame 031238/0307 →